High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Abstract

Background: Overexpression of dedicator of cytokinesis 1 (DOCK1) has been confirmed as an unfavorable prognostic marker in acute myeloid leukemia (AML). Purpose: This study is to explore the clinical implications of DOCK1 on AML patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients and methods: We analyzed 71 de novo AML patients treated with allo-HSCT and divided them into two groups (DOCK1 high vs DOCK1 low) by the median expression level of DOCK1. Results: High DOCK1 expression was associated with older age (P=0.019), wild-type CEBPA (P=0.002), IDH1/2 mutations (P=0.010) and RUNX1 mutation (P=0.005). Univariate analyses showed that DOCK1 high and RUNX1 mutation were associated with shorter OS (P<0.001, P=0.024). Multivariate analysis confirmed the negative effect of high DOCK1 level on overall survival (P=0.010). Conclusion: Our results demonstrate that in AML patients who received allo-HSCT, high DOCK1 expression might have a persistent negative prognostic impact post-transplant.

• Authors: Gaoqi Zhang, Jilei Zhang, Xinrui Yang, Xinpei Zhang, Siyuan Yang, Jing Wang, Kai Hu, Jinlong Shi, Xiaoyan Ke, Lin Fu
• Journal: Cancer management and research (Cancer Manag Res) Vol. 11 Pg. 3053-3060 ( 2019) ISSN: 1179-1322 [Print] New Zealand
• PMID: 31114350 (Publication Type: Journal Article)